Modafinil Bluefish

Modafinil, the active ingredient in Modafinil Bluefish, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It treats narcolepsy, excessive daytime sleepiness associated with obstructive sleep apnea, and shift work sleep disorder in adults.

GNH USA supplies Modafinil Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil acts on the central nervous system to promote wakefulness in sleep‑related disorders.

Narcolepsy: reduces daytime sleep attacks and improves overall alertness. Obstructive sleep apnea‑related excessive daytime sleepiness: alleviates residual sleepiness when used alongside primary apnea therapy. Shift work sleep disorder: helps maintain alertness during scheduled work hours.

Modafinil may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Headache - Nausea - Insomnia - Anxiety - Dry mouth - Dizziness

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Psychiatric disturbances (e.g., mania, hallucinations) - Cardiovascular events (e.g., hypertension, arrhythmia) - Anaphylactic or severe allergic reactions - Elevated liver enzymes or hepatitis - Suicidal thoughts or behavior

When prescribing Modafinil, clinicians should consider several safety measures.

Assess cardiovascular status: evaluate blood pressure and heart disease before initiating. Monitor psychiatric history: exercise caution in patients with anxiety, depression, or other mental health conditions. Avoid use in uncontrolled hypertension: consider alternative therapy for patients with high blood pressure. Do not co‑administer with strong CYP3A4 inhibitors: these may increase plasma concentrations of Modafinil. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Modafinil can influence, or be influenced by, other medicines through metabolic pathways.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise Modafinil concentrations. - CNS depressants (e.g., benzodiazepines, alcohol): may counteract the wake‑promoting effect. - Monoamine oxidase inhibitors: risk of hypertensive crisis.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce Modafinil efficacy. - Oral contraceptives: Modafinil may decrease hormonal effectiveness. - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome.